These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Regional brain metabolism as the predictor of performance on the Trail Making Test in schizophrenia. A 18FDG PET covariation study. Horacek J; Dockery C; Kopecek M; Spaniel F; Novak T; Tislerova B; Klirova M; Palenicek T; Höschl C Neuro Endocrinol Lett; 2006 Oct; 27(5):587-94. PubMed ID: 17159818 [TBL] [Abstract][Full Text] [Related]
23. Involvement of neuropeptide systems in schizophrenia: human studies. Cáceda R; Kinkead B; Nemeroff CB Int Rev Neurobiol; 2007; 78():327-76. PubMed ID: 17349866 [TBL] [Abstract][Full Text] [Related]
24. Alterations of serotonin transmission in schizophrenia. Abi-Dargham A Int Rev Neurobiol; 2007; 78():133-64. PubMed ID: 17349860 [TBL] [Abstract][Full Text] [Related]
25. [Metabolic changes in schizophrenia]. Insua JA Prensa Med Argent; 1965 May; 52(15):905-15. PubMed ID: 5844239 [No Abstract] [Full Text] [Related]
26. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Javitt DC Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858 [TBL] [Abstract][Full Text] [Related]
27. Expression pattern of STOP lacZ reporter gene in adult and developing mouse brain. Couégnas A; Schweitzer A; Andrieux A; Ghandour MS; Boehm N J Neurosci Res; 2007 May; 85(7):1515-27. PubMed ID: 17394261 [TBL] [Abstract][Full Text] [Related]
28. Presynaptic proteins and schizophrenia. Honer WG; Young CE Int Rev Neurobiol; 2004; 59():175-99. PubMed ID: 15006488 [No Abstract] [Full Text] [Related]
29. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Miller CL; Llenos IC; Cwik M; Walkup J; Weis S Neurochem Int; 2008 May; 52(6):1297-303. PubMed ID: 18328600 [TBL] [Abstract][Full Text] [Related]
30. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Weickert CS; Straub RE; McClintock BW; Matsumoto M; Hashimoto R; Hyde TM; Herman MM; Weinberger DR; Kleinman JE Arch Gen Psychiatry; 2004 Jun; 61(6):544-55. PubMed ID: 15184234 [TBL] [Abstract][Full Text] [Related]
31. S100B in schizophrenic psychosis. Rothermundt M; Ponath G; Arolt V Int Rev Neurobiol; 2004; 59():445-70. PubMed ID: 15006498 [TBL] [Abstract][Full Text] [Related]
32. [New pharmacological approaches to the treatment of schizophrenia]. Uzbay IT Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368 [TBL] [Abstract][Full Text] [Related]
33. Metabolic relationship of succinate and pyruvate in brain tissue with special reference to the potassium effect. ITO K Jpn J Exp Med; 1960 Aug; 30():261-77. PubMed ID: 13718112 [No Abstract] [Full Text] [Related]
35. Brain activation during affective visual cues in schizophrenia: a pilot study using FMRI. Wilson WH; Bigelow DA J Clin Psychopharmacol; 2004 Aug; 24(4):450-2. PubMed ID: 15232340 [No Abstract] [Full Text] [Related]
36. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Woo TU; Walsh JP; Benes FM Arch Gen Psychiatry; 2004 Jul; 61(7):649-57. PubMed ID: 15237077 [TBL] [Abstract][Full Text] [Related]
37. Molecular mechanism of schizophrenia with reference to disrupted-in-schizophrenia 1 (DISC1). Matsuzaki S; Tohyama M Neurochem Int; 2007; 51(2-4):165-72. PubMed ID: 17664024 [TBL] [Abstract][Full Text] [Related]
38. Repeated injection of MK801: an animal model of schizophrenia? Eyjolfsson EM; Brenner E; Kondziella D; Sonnewald U Neurochem Int; 2006; 48(6-7):541-6. PubMed ID: 16517016 [TBL] [Abstract][Full Text] [Related]
39. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214 [TBL] [Abstract][Full Text] [Related]
40. Dopamine-glutamate abnormalities in the frontal cortex associated with the catechol-O-methyltransferase (COMT) in schizophrenia. Brisch R; Bernstein HG; Krell D; Dobrowolny H; Bielau H; Steiner J; Gos T; Funke S; Stauch R; Knüppel S; Bogerts B Brain Res; 2009 May; 1269():166-75. PubMed ID: 19268435 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]